SLIDE 1
PALAIS DES CONGRES DE VICHY. 20 au 22 Juin 2019 TESTING IN PATIENTS - - PowerPoint PPT Presentation
PALAIS DES CONGRES DE VICHY. 20 au 22 Juin 2019 TESTING IN PATIENTS - - PowerPoint PPT Presentation
PALAIS DES CONGRES DE VICHY. 20 au 22 Juin 2019 TESTING IN PATIENTS WITH SUSPECTED CAD: CCTA PERFORMS BETTER THAN FUNCTIONAL TESTS? Dr L. MACRON, Dr J. FEIGNOUX, Dr J-L. SABLAYROLLES Centre Cardiologique du Nord (CCN). Saint-Denis. France.
SLIDE 2
SLIDE 3
- 1. EXISTE T’IL UNE CORONAROPATHIE?
- 2. QUELLE EST LA SÉVÉRITÉ DE LA CORONAROPATHIE?
- 3. FAUT-IL INTRODUIRE UN TRAITEMENT MEDICAL?
- 4. FAUT-IL REVASCULARISER CE PATIENT?
PATIENTS WITH SYMPTOMS SUGGESTIVE OF CORONARY ARTERY DISEASE (CAD)
?
SLIDE 4
2014 ESC/EACTS Guidelines on myocardial revascularization
SLIDE 5
Pre-test likelihood of CAD according to the updated Diamond-Forrester risk model score
ESC guidelines 2013 on the management of stable CAD
SLIDE 6
ASSESSMENT OF PTP: HOW FAR WE ARE FROM…
CONFIRM registry Observed vs Expected Prevalence of coronary stenosis >50% . Overall population: 18% vs 51% . Atypical angina: 15% vs 47% . Typical angina: 29% vs 86%
SLIDE 7
Arbab-Zadeh. Heart International 2012; vol 7:e2
Results from: Underwood et al. Eur J Nucl Med Mol Imaging 2004 – Gianrossi et al. Circulation 1989 – Fleischmann et al. JAMA 1998 – Geleinjnse et al. J Am Soc Echocardiogr 2009
Se 80-90% ; Sp 70-80% (stress test with imaging)
ACCURACY OF STRESS TESTING FOR DETECTING OBSTRUCTIVE CAD
SLIDE 8
ESC guidelines 2013 on the management of stable CAD
SLIDE 9
83.9% of NIT prior ICA From Patel et al. N Engl J Med 2010. 362; 10
= LOW DIAGNOSTIC YIELD OF ELECTIVE ICA
SLIDE 10
From Marwick et al. JACC 2015
CCTA DIAGNOSTIC VALUE
94-99% 64-83% 97-99%
“A CT-based approach can effectively rule out anatomic CAD”
Arbab-Zadeh. Heart International 2012
Results from the Meta-analysis of Paech et. BMC Cardiovasc Disord 2011including 3,674 symptomatic patients without history of coronary artery disease enrolled in 28 studies.
42-81%
SLIDE 11
CCTA PROGNOSTIC VALUE
Hulten et al. JACC 2011 No CAD-specific events in the group of normal CCTA n=9592pts; median follow-up 20 months
SLIDE 12
CCTA PROGNOSTIC VALUE
Hulten et al. JACC 2011 No CAD-specific events in the group of normal CCTA Annual event rate 0.16% normal CCTA ≈ background event rate among healthy low-risk individuals
SLIDE 13
Arbab-Zadeh. Heart International 2012; vol 7:e2
Results from: Navare et al. J Nucl Cardiol 2004 – Metz et al. JACC 2007 – Peteiro et al. Am Heart J 2006 – Bangalore et al. J Am Soc Echocardiogr 2007
≈18%MI and CV death/10y. 10M stress tests/year in the US 7M normal stress tests/year 70000 MI and cardiac death/year AFTER A NORMAL STRESS TEST
70% normal test AER 1% after normal test
PROGNOSTIC VALUE OF STRESS TESTING
SLIDE 14
Chang SM JACC 2009; Arbab Zadeh Circulation 2014
NORMAL SPECT >2% AER if CAC>400 HIGH RISK FOR CARDIAC EVENTS DESPITE NORMAL STRESS TEST
SLIDE 15
“Absence d’ischémie myocardique au cours d’une épreuve d’effort maximale négative”
SLIDE 16
SLIDE 17
CCTA PROGNOSTIC VALUE
Hulten et al. JACC 2011 Event rate ≈ 4% for CCTA obstructive similar to abnormal SPECT
SLIDE 18
CCTA PROGNOSTIC VALUE
Hulten et al. JACC 2011 Non obstructive CAD ≈ 1% death/MI per year
SLIDE 19
Annualized event rate 1% for NON-OBSTRUCTIVE CAD ≈ normal stress test
CCTA PROGNOSTIC VALUE
BENEFITS OF CCTA vs. STRESS TESTING
1.Categorization of no CAD, non-obstructive CAD and obstructive-CAD 2.Identification of a subgroup (38%) of patients who are at exceedingly low risk of adverse events (No CAD) 3.Identification of a subgroup (34%) of patients who may benefit from medical treatment
SLIDE 20
Schwitter J. Eur Heart J 2011
RISK STRATIFICATION IN SUSPECTED CAD : THE PARADIGM OF ISCHEMIA
INCREASE IN CARDIAC DEATH/MYOCARDIAL INFARCTION AS A FUNCTION OF ISCHEMIA
?
IS IT REALLY ISCHEMIA THAT CONFERS RISK OF ADVERSE EVENTS?
SLIDE 21
Chang SM JACC 2009; Arbab Zadeh Circulation 2014
NORMAL SPECT >2% AER if CAC>400 HIGH RISK FOR CARDIAC EVENTS DESPITE NORMAL STRESS TEST
SLIDE 22
RISK STRATIFICATION IN SUSPECTED CAD : THE PARADIGM OF ATHEROSCLEROTIC BURDEN
SLIDE 23
RISK STRATIFICATION IN SUSPECTED CAD : THE PARADIGM OF ATHEROSCLEROTIC BURDEN MORTALITY is strongly related to PRESENCE/EXTENT of CAC Ostrom et al. JACC 2008 Adapted from Budoff et al. JACC 2009 CV EVENTS are strongly related to PRESENCE/EXTENT of CAD
SLIDE 24
RISK STRATIFICATION IN SUSPECTED CAD : THE PARADIGM OF ATHEROSCLEROTIC BURDEN
>10 000 pt. ICA Events: CV death, MI, HF, stroke >3 000 pt. CCTA. Median FU 3.6y Extensive non-obstructive = at least 4 segments
SLIDE 25
RISK STRATIFICATION IN SUSPECTED CAD : THE PARADIGM OF ATHEROSCLEROTIC BURDEN
SLIDE 26
Mancini et al JACC CV interv. 2014
« anatomic burden was a consistent predictor
- f death, MI, and NSTE-ACS, whereas ischemic
burden was not » Ischemic burden Anatomic burden
SLIDE 27
Low event rate (1.05%/y) Short follow-up (>12 months; median 25 months) Fewer ICA without obstructive CAD . CCTA + >>> 72.1% obstructive CAD . Functional test + >>> 47.5% obstructive CAD = HIGHER ACCURACY for CCTA Lower radiation exposure compared to SPECT group (12.0±8.4 mSv vs. 14.1±7.6 mSv) Lower MI rates (borderline statistical significance)
SLIDE 28
- Lancet. June 2015
Fordyce, C.B. et al. J Am Coll Cardiol. 2016
n = 4142 patients Diagnosis of CHD: 27% reclassification Changes in investigations: 15% Changes in treatments: 23% 38 % reduction in fatal and non fatal MI (1.7y follow up – p=0.0527) ≈50% reduction CV event rate at 3 years follow up (1.7 vs 2.5%)
SLIDE 29
SLIDE 30
Median FU: 8y - Similar rates of ICA & revasc. 41% MI reduction CCTA vs UC
SLIDE 31
SLIDE 32
SLIDE 33